[1]Liu J, Liang L. The association between thyroid and breast cancers: a bidirectional mendelian randomization study. Front Endocrinol (Lausanne). 14:1185497. Published 2023 None. doi:10.3389/fendo.2023.1185497
[2]Tran TV, Maringe C, Benitez Majano S, Rachet B, Boutron-Ruault MC, Journy N. Thyroid dysfunction and breast cancer risk among women in the UK Biobank cohort.Cancer Med. 2021;10(13):4604-4614. doi:10.1002/cam4.3978
[3]Ding J, Li W, Que Y. Correlative Study on the Association Between Breast Cancer and Autoimmune Thyroid Disease. Altern Ther Health Med. . Published online Jun 28,2024.

[4] Xu JX, Chen YY, Qi LN, Peng YC. Investigation of the causal relationship between breast cancer and thyroid cancer: a set of two-sample bidirectional Mendelian randomization study. Endocrine. 2025;87(1):196-205. doi:10.1007/s12020-024-03976-0
[5] Bakos B, Kiss A, Árvai K, et al. Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden. BMC Cancer. 2021;21(1):706. Published 2021 Jun 15. doi:10.1186/s12885-021-08377-4
[6] Tran TV, Rubino C, Allodji R, et al. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. Br J Cancer. 2022;127(12):2118-2124. doi:10.1038/s41416-022-01982-5
[7] Nguyen TMT, Pham HNH, Do TA, Pham KH, Van Nguyen C. Metachronous papillary thyroid carcinoma and hereditary breast carcinoma with BRCA1 mutation in a Vietnamese woman: A case report. Int J Surg Case Rep. 106:108249.doi:10.1016/j.ijscr.2023.108249
[8] Song CM, Kim YJ, Cheong HS, Ji YB, Tae K. Single-Nucleotide Polymorphisms of BRCA1 and BRCA2 and Risk of Papillary Thyroid Carcinoma. Cancers (Basel). 2025;17(9). Published 2025 Apr 26. doi:10.3390/cancers17091456
[9]Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S, Massimino M, Giuliano M, Vigneri P. REThinking the role of the RET oncogene in breast cancer. Front Oncol. 2024 Aug 1;14:1427228. doi: 10.3389/fonc.2024.1427228. PMID: 39211557; PMCID: PMC11358597.
[10]Shi M, Wang W, Zhang J, Li B, Lv D, Wang D, Wang S, Cheng D, Ma T. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer Sci. 2022 Jan;113(1):308-318. doi: 10.1111/cas.15181. Epub 2021 Nov 15. PMID: 34710947; PMCID: PMC8748217.
[11]Cerrato A, Visconti R, Celetti A. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. Mol Cancer. 2018 Feb 19;17(1):46. doi: 10.1186/s12943-018-0799-8. PMID: 29455670; PMCID: PMC5817729.
[12]Kohno T, Tabata J, Nakaoku T. REToma: a cancer subtype with a shared driver oncogene. Carcinogenesis. 2020 Apr 22;41(2):123-129. doi: 10.1093/carcin/bgz184. PMID: 31711124.
[13]Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67. doi: 10.1016/j.cytogfr.2005.05.010. PMID: 15982921.
[14]Wu J, Subbiah V. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 Oct 2;83(19):3159-3161. doi: 10.1158/0008-5472.CAN-23-1021. PMID: 37779428; PMCID: PMC12087442.
[15] Voutsadakis IA. The TSH/Thyroid Hormones Axis and Breast Cancer. J Clin Med. 2022;11(3). Published 2022 Jan 28. doi:10.3390/jcm11030687
[16] Jia X, Li J, Jiang Z. Association between thyroid disorders and extra-thyroidal cancers, a review. Clin Transl Oncol. 2024;26(9):2075-2083. doi:10.1007/s12094-024-03434-3
[17] Sandsveden M, Borgquist S, Rosendahl AH, Manjer J. Low thyroid hormone receptor alpha-2 (THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality. Breast Cancer Res. 2021;23(1):117. Published 2021 Dec 20. doi:10.1186/s13058-021-01496-7
[18] Yang H, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. BMC Med. 2020;18(1):225. Published 2020 Aug 25. doi:10.1186/s12916-020-01690-y
[19] Jensen A, Gottschau M, Christensen J, et al. Risk of breast cancer among women with hypo- and hyperthyroidism: Results from a large nationwide cohort study. Int J Cancer. . Published online Jun 23,2025. doi:10.1002/ijc.70007
[20] Gong Z, Yang S, Wei M, et al. The Isoforms of Estrogen Receptor Alpha and Beta in Thyroid Cancer. Front Oncol. 12:916804. Published 2022 None. doi:10.3389/fonc.2022.916804
[21] Kim M, Kim SJ, Ha SY, et al. BRAFV600E Mutation Enhances Estrogen-Induced Metastatic Potential of Thyroid Cancer by Regulating the Expression of Estrogen Receptors. Endocrinol Metab (Seoul). 2022;37(6):879-890. doi:10.3803/EnM.2022.1563
[22] Meci A, Lorenz FJ, Goyal N, Goldenberg D. Elevated Risk of Thyroid Malignancy in Biological Males Taking Estrogen Hormone Therapy. Otolaryngol Head Neck Surg. 2025;172(4):1192-1198. doi:10.1002/ohn.1128
[23] Zhu X, Xue C, Kang X, et al. DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis, growth and metastasis. Int J Biol Sci. 2022;18(11):4372-4387. Published 2022 None. doi:10.7150/ijbs.72397
[24] Liu J, Xu T, Ma L, Chang W. Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer. Front Oncol. 11:593479. Published 2021 None. doi:10.3389/fonc.2021.593479
[25] Graceffa G, Scerrino G, Militello G, et al. Breast cancer in previously thyroidectomized patients: which thyroid disorders are a risk factor? Future Sci OA. 2021;7(5):FSO699. Published 2021 Mar 29. doi:10.2144/fsoa-2021-0029
[26] Baldini E, Lauro A, Tripodi D, et al. Thyroid Diseases and Breast Cancer. J Pers Med. 2022;12(2). Published 2022 Jan 25. doi:10.3390/jpm12020156
[27] Gendelman O, Tripto-Shkolnik L, Vered I, Lidar M. Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature. Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):1995-1999. doi:10.1080/09273948.2021.1922705
[28] Scherübl H. [Metabolic syndrome and cancer risk]. Dtsch Med Wochenschr. 2022;147(16):1068-1077. doi:10.1055/a-1868-9164
[29] Halada S, Casado-Medrano V, Baran JA, et al. Hormonal Crosstalk Between Thyroid and Breast Cancer. Endocrinology. 2022;163(7). doi:10.1210/endocr/bqac075
[30] Lathigara D, Kaushal D, Wilson RB. Molecular Mechanisms of Western Diet-Induced Obesity and Obesity-Related Carcinogenesis-A Narrative Review. Metabolites. 2023;13(5). Published 2023 May 21. doi:10.3390/metabo13050675
[31] Guevara-Aguirre J, Peña G, Pazmiño G, et al. Cancer in Ecuadorian subjects with Laron syndrome (ELS). Endocr Relat Cancer. 2023;30(6). Published 2023 Jun 1. doi:10.1530/ERC-22-0389
[32] Zou Y, Pitchumoni CS. Obesity, obesities and gastrointestinal cancers. Dis Mon. 2023;69(12):101592. doi:10.1016/j.disamonth.2023.101592